科研之友
微信
新浪微博
Facebook
分享链接
摘要
Lung cancer is the leading cause of cancer death, and five-year survival remains poor, raising the urgency for new treatment strategies. Activation of PPAR gamma represents a potential target for both the treatment and prevention of lung cancer. Numerous studies have examined the effect of thiazolidinediones such as rosiglitazone and pioglitazone on lung cancer cells in vitro and in xenograft models. These studies indicate that activation of PPAR gamma inhibits cancer cell proliferation as well as invasiveness and metastasis. While activation of PPAR gamma can occur by direct binding of pharmacological ligands to the molecule, emerging data indicate that PPAR gamma activation can occur through engagement of other signal transduction pathways, including Wnt signaling and prostaglandin production. Data, both from preclinical models and retrospective clinical studies, indicate that activation of PPAR gamma may represent an attractive chemopreventive strategy. This article reviews the existing biological and mechanistic experiments focusing on the role of PPAR gamma in lung cancer, focusing specifically on nonsmall cell lung cancer.
- 出版日期2008
